JP2019516748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516748A5 JP2019516748A5 JP2018561278A JP2018561278A JP2019516748A5 JP 2019516748 A5 JP2019516748 A5 JP 2019516748A5 JP 2018561278 A JP2018561278 A JP 2018561278A JP 2018561278 A JP2018561278 A JP 2018561278A JP 2019516748 A5 JP2019516748 A5 JP 2019516748A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell carcinoma
- inhibitor
- seq
- renal cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341921P | 2016-05-26 | 2016-05-26 | |
| US62/341,921 | 2016-05-26 | ||
| US201662423358P | 2016-11-17 | 2016-11-17 | |
| US62/423,358 | 2016-11-17 | ||
| US201762471459P | 2017-03-15 | 2017-03-15 | |
| US62/471,459 | 2017-03-15 | ||
| PCT/EP2017/062213 WO2017202744A1 (en) | 2016-05-26 | 2017-05-22 | Pd-1 / pd-l1 inhibitors for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516748A JP2019516748A (ja) | 2019-06-20 |
| JP2019516748A5 true JP2019516748A5 (https=) | 2020-07-02 |
Family
ID=58745241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561278A Pending JP2019516748A (ja) | 2016-05-26 | 2017-05-22 | がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190144545A1 (https=) |
| EP (1) | EP3464356A1 (https=) |
| JP (1) | JP2019516748A (https=) |
| KR (1) | KR20190012201A (https=) |
| CN (1) | CN109195989A (https=) |
| AU (1) | AU2017269675A1 (https=) |
| BR (1) | BR112018073920A2 (https=) |
| CA (1) | CA3025391A1 (https=) |
| IL (1) | IL263178A (https=) |
| MX (1) | MX2018014435A (https=) |
| RU (1) | RU2018145184A (https=) |
| SG (1) | SG11201810423XA (https=) |
| TW (1) | TW201800108A (https=) |
| WO (1) | WO2017202744A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| NZ733854A (en) | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| PH12017501857B1 (en) | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| KR20190062515A (ko) * | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| MX2021005236A (es) * | 2018-11-05 | 2021-06-18 | Merck Sharp & Dohme Llc | Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer. |
| EP3876940A1 (en) * | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinations for treating cancer |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| BR112022001045A2 (pt) * | 2019-07-22 | 2022-07-19 | Seagen Inc | Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| BR112022022335A2 (pt) | 2020-05-05 | 2023-01-10 | Teon Therapeutics Inc | Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| KR20230128690A (ko) * | 2022-02-28 | 2023-09-05 | 주식회사 시선테라퓨틱스 | 핵산 복합체를 포함하는 폐암 예방 또는 치료용 조성물 |
| EP4554943A1 (en) | 2022-07-14 | 2025-05-21 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| WO2026035860A1 (en) | 2024-08-07 | 2026-02-12 | Teon Therapeutics, Inc. | Formulations of adenosine receptor antagonist |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| HRP20201595T1 (hr) * | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| NZ718821A (en) * | 2013-09-11 | 2022-07-01 | Medimmune Ltd | Anti-b7-h1 antibodies for treating tumors |
| SG11201700074YA (en) * | 2014-07-15 | 2017-02-27 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| NZ733854A (en) * | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| PH12017501857B1 (en) * | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
-
2017
- 2017-05-22 AU AU2017269675A patent/AU2017269675A1/en not_active Abandoned
- 2017-05-22 CA CA3025391A patent/CA3025391A1/en not_active Abandoned
- 2017-05-22 MX MX2018014435A patent/MX2018014435A/es unknown
- 2017-05-22 WO PCT/EP2017/062213 patent/WO2017202744A1/en not_active Ceased
- 2017-05-22 SG SG11201810423XA patent/SG11201810423XA/en unknown
- 2017-05-22 KR KR1020187037522A patent/KR20190012201A/ko not_active Withdrawn
- 2017-05-22 RU RU2018145184A patent/RU2018145184A/ru not_active Application Discontinuation
- 2017-05-22 US US16/304,338 patent/US20190144545A1/en not_active Abandoned
- 2017-05-22 CN CN201780032522.1A patent/CN109195989A/zh active Pending
- 2017-05-22 EP EP17724821.8A patent/EP3464356A1/en not_active Withdrawn
- 2017-05-22 JP JP2018561278A patent/JP2019516748A/ja active Pending
- 2017-05-22 BR BR112018073920-0A patent/BR112018073920A2/pt not_active Application Discontinuation
- 2017-05-25 TW TW106117304A patent/TW201800108A/zh unknown
-
2018
- 2018-11-21 IL IL263178A patent/IL263178A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516748A5 (https=) | ||
| Pento | Monoclonal antibodies for the treatment of cancer | |
| RU2018145184A (ru) | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования | |
| JP2020508317A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| JP2020529469A5 (https=) | ||
| JP2019508433A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| Yoon et al. | Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy | |
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| JP2020500161A5 (https=) | ||
| EP3463456A1 (en) | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers | |
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 | |
| EP3920970B2 (en) | Method for treating checkpoint inhibitors induced adverse events | |
| US20190290776A1 (en) | Non-adult human dosing of anti-cd30 antibody-drug conjugates | |
| WO2021119105A1 (en) | Combination therapy with liv1-adc and pd-1 antagonist | |
| JPWO2020223702A5 (https=) | ||
| Kubiatowski et al. | Lung cancer immunotherapy in transplant patients and in patients with autoimmune diseases | |
| JP7064544B2 (ja) | 癌の治療のための抗ｖｅｇｆｒ－２抗体と抗ｐｄ－ｌ１抗体との組み合わせ | |
| JPWO2021229234A5 (https=) | ||
| EP4520333A1 (en) | Syk inhibitors for use in the treatment of immune checkpoint inhibition induced adverse events | |
| CN111093703A (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 |